Dr Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics, Inc. before its trade sale to iBio, Inc. (NYSEA: IBIO) in September 2022. Prior to launching Rubric, Dr Bright was Chief Business Officer for molecular diagnostics innovator Health Tell, Inc., driving its trade sale to iCarbonX, concomitant with RubrYcs launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics, Inc. and consoling Chief Business Officer for synthetic biology innovator musebio, Inc. (currently Incripta, Inc.)Dr Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016. With Merieux, Dr Bright led investments and Board representation for Imaginab, Inc., Kalila Medical, Inc. its acquisition by Abbo (NYSE: ABT), and Twist Bioscience before its IPO (NASDAQ: TWST). Dr Brights startup experience began as he built and led QuantaLife, Inc.s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLifes acquisition by Bio-Rad Laboratories, Inc. (NYSE: BIO). Previously, Dr Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic (NYSE: MDT).
